Capnia, a Palo Alto, Calif., company that delivers carbon dioxide through a patient’s nose to treat things like migraines and rhinitis, has raised $16.3 million of a potential $19 million third round of funding.
Backers include existing investors Vivo Ventures, Asset Management and Teknoinvest, as well as individuals including chief executive Ernest Mario, according to VentureWire, which first reported the news.
The company said the money will help the company finish the second phase of trials for its product.
The company had previously raised more than $20 million.
VentureBeatVentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative technology and transact. Our site delivers essential information on data technologies and strategies to guide you as you lead your organizations. We invite you to become a member of our community, to access:
- up-to-date information on the subjects of interest to you
- our newsletters
- gated thought-leader content and discounted access to our prized events, such as Transform 2021: Learn More
- networking features, and more